Efficacy of different formulations of nystatin in an experimental model of oral candidiasis in sialoadenectomized rats

Abstract

Background/purpose Oral candidiasis is the most common fungal infection of the oral cavity and has become a focus of attention in recent years because of its association with highly topical immunosuppressive conditions. The aims of this study were to determine the value of microbiological, clinical and histological parameters of Candida albicans colonisation of the dorsal tongue surface as indicators of disease severity, and to evaluate therapeutic response to different formulations of nystatin. Materials and methods We used 84 males, 2-month-old Sprague–Dawley sialoadenectomized rats. Different formulations of nystatin were used to evaluate the therapeutic response. The animals were randomized to 2 groups with each of 42 animals and received the experimental treatments from day 17–22. Results 100% of the rats showed evidence of infection. At 5 and 10 days of starting treatment with nystatin + chitosan, and at 10 days of starting nystatin + orabase, the number of animals with positive dorsal tongue culture decreased significantly (p < 0.05), acting the Nystatin + chitosan more rapidly against Candida . In the control group, the percentage of normal papillae on day 22 and 27 was 83.33% (SD = 1.50) and 79.08% (SD = 2.30), respectively. Significant differences were observed in the mean O'Grady score at 5 and 10 days (p < 0.0001). Conclusion The model has been shown to be effective in inducing infection, and that the combination of nystatin and chitosan yielded the best therapeutic outcomes at both 5 and 10 days after infection.

Evaluation of Topical Application of Nanocurcumin Suspension in Treatment of Oral Candidal Infection (Experimental Study)

“…In our study, we used the antifungal nystatin in a positive control group as a comparison parameter because it is considered the most commonly used topical antifungal for the treatment of oral candidiasis (31). In another study used topical nystatin once daily, all animals showed partial remission of lesions after 5 days of treatment (32). In contrary, 69% of the animals showed total remission of the lesion after 5 days of treatment.…”

In Vivo Efficacy of Lacticaseibacillus rhamnosus L8020 in a Mouse Model of Oral Candidiasis

“…Furthermore, animal model experiments and clinical studies provide important data regarding the efficacies of probiotics. Several animal models of oral, gastrointestinal and vaginal candidiasis have been proposed for analyses of fungal immunity and anti-fungal therapies [11,17,18,[21][22][23][24][25][26][27]. These animal models have aided in elucidating molecular mechanisms related to candidiasis; they have also facilitated the evaluation of novel therapeutic approaches.…”

Polyhydroxyalkanoate/Antifungal Polyene Formulations with Monomeric Hydroxyalkanoic Acids for Improved Antifungal Efficiency

“…Nystatin is a polyene antifungal drug that is of particular interest because it exhibits remarkable action against a wide range of pathogenic and non-pathogenic yeast and fungi and it is used in severely immune compromised patients and neonates [ 33 , 34 , 35 ]. While different formulations of nystatin have been developed [ 36 ], the topical formulation of nystatin remains the most widespread in clinical use [ 37 ]. Amphotericin B deoxycholate has been the “gold standard” treatment for invasive fungal infections for over 50 years [ 31 , 38 , 39 ].…”